Letrozole Tablet In Kolkata

MOQ10 Box/Boxes

Drug TypeGeneral Medicines

Physical FormTablets

Suitable ForSuitable For All

Storage InstructionsCool & Dry Place

MOQ100 Box/Boxes

Drug TypeSpecific Drug

Physical FormTablets

DosageAs Directed By The Physician

Dosage GuidelinesAs Per Doctor Prescription

Suitable ForAdults

Storage InstructionsCool And Dry Place

MOQ100 Unit/Units

Supply Ability100000 Per Month

Delivery Time10-15 Days

MOQ100 Strip/Strips

Pacakaging (Quantity Per Box)10*10 Tablets

Origin of MedicineIndia

Physical FormTablets

Dosage2.5 mg

Dosage GuidelinesPrescription

Suitable ForAdults Aged Person

MOQ100 Box/Boxes

Drug TypeGeneral Medicines

Physical FormTablets

Dosage GuidelinesAs per the doctor's advice

Storage InstructionsKeep at cool and Dry Place

MOQ10 Strip/Strips

Origin of MedicineSynthetic

Pacakaging (Quantity Per Box)10 strips per box

Salt CompositionLetrozole 2.5mg

Drug TypeOther Anti-cancer medication

IngredientsLetrozole

Physical FormOther Tablet

MOQ100 Unit/Units

Dosage FormTablet

OriginIndia

Fermentation SmellNormal Smell

Storage InstructionsDry place

Shelf Life12-24 Months

MOQ1 Strip/Strips

IngredientsOther

ApplicationOther

Storage InstructionsCool & Dry Place

Dosage2.5 mg

Tablet count10 tablets

PackagingCarton box

ColorWhite

Active ingredientLetrozole

FeaturesEffective treatment Dosage accuracy Convenient packaging Reliable source 2.5mg tablets

Dosage2.5mg

Quantity30 tablets

TypeTablet

ShapeRound

ColorYellow

PackagingBlister pack

Tablet ShapeRound

PackagingBlister pack

Dosage2.5mg

Active IngredientLetrozole

StorageCool Dry place

FeaturesCancer prevention First treatment High quality Effective Reliable Safe

MOQ10 Box/Boxes

Drug TypeSpecific Drug

IngredientsLETROZOLE 2.5MG

Physical FormTablets

FunctionCancer Treatment

Recommended ForBREAST CANCERINFERTILITY DUE TO ANOVULATION

Dosagedult and elderly patients The recommended dose of Letrozole Tablets is 2.5 mg once daily. No dose adjustment is required for elderly patients. In patients with advanced or metastatic breast cancer treatment with Letrozole Tablets should continue until tumour progression is evident. In the adjuvant and extended adjuvant setting treatment with Letrozole Tablets should continue for 5 years or until tumour relapse occurs whichever is first. In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered (see sections 4.4 and 5.1). In the neoadjuvant setting treatment with Letrozole tablet could be continued for 4 to 8 months in order to establish optimal tumour reduction. If the response is not adequate treatment with Letrozole tablet should be discontinued and surgery scheduled and/or further treatment options discussed with the patient.